These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 1574961)

  • 1. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous.
    Hörl WH
    Acta Haematol; 1992; 87 Suppl 1():16-9. PubMed ID: 1574961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin.
    McMahon LP; Dawborn JK
    Am J Nephrol; 1990; 10(5):404-8. PubMed ID: 2080791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to get the best out of r-HuEPO.
    Macdougall IC
    Nephrol Dial Transplant; 1995; 10 Suppl 2():85-91. PubMed ID: 7644112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darbepoetin alfa.
    Ibbotson T; Goa KL
    Drugs; 2001; 61(14):2097-104; discussion 2105-6. PubMed ID: 11735636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients.
    Cervelli MJ; Gray N; McDonald S; Gentgall MG; Disney AP
    Nephrology (Carlton); 2005 Apr; 10(2):129-35. PubMed ID: 15877671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin.
    Salmonson T
    Scand J Urol Nephrol Suppl; 1990; 129():1-66. PubMed ID: 2255869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY; Chu TS; Huang JW; Wu MS; Wu KD
    J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients.
    Nephron; 1992; 61(4):399-403. PubMed ID: 1501735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.
    Lui SF; Wong KC; Li PK; Lai KN
    Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
    Frenken LA; Verberckmoes R; Michielsen P; Koene RA
    Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment.
    Hughes RT; Cotes PM; Pippard MJ; Stevens JM; Oliver DO; Winearls CG; Royston JP
    Br J Haematol; 1990 Jun; 75(2):268-73. PubMed ID: 2372513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Law CB; Ting SM; Li P; Lai KN
    Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin.
    Howarth JE; Waters HM; Shanks D; Hyde K; Yin JA; Geary CG; Anastassiades E; Howarth D; Gokal R
    J Clin Pathol; 1993 Jan; 46(1):41-4. PubMed ID: 8432886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial.
    Sweeney PJ; Nicolae D; Ignacio L; Chen L; Roach M; Wara W; Marcus KC; Vijayakumar S
    Br J Cancer; 1998 Jun; 77(11):1996-2002. PubMed ID: 9667681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study].
    Ruedin P; Stoerman C; Pechère-Bertschi A; Leski M
    Nephrologie; 1992; 13(2):87-92. PubMed ID: 1608502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to get the best out of r-HuEPO.
    Hörl WH
    Nephrol Dial Transplant; 1995; 10 Suppl 2():92-5. PubMed ID: 7644113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics.
    Cotes PM; Pippard MJ; Reid CD; Winearls CG; Oliver DO; Royston JP
    Q J Med; 1989 Feb; 70(262):113-37. PubMed ID: 2594953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.